StockData

Inmune Bio vs Senti Biosciences

INMB and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INMB and SNTI compare

Inmune Bio is the larger company, worth 8.8 times as much as Senti Biosciences ($26.6M against $3.0M).

Inmune Bio scores higher on the StockData Score (6 against 4 for Senti Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINMBSNTI
Size and price
Market cap$26.6M$3.0M
Share price$0.960$0.097
Change, 1 year−32.4%−94.0%
Change, 5 years−92.8%−99.9%
Beta (5Y)2.983.17
Employees6–
StockData Score
Total score6 (better)4
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/B1.3×–
Growth
Revenue growth, 5Y average35.4%–
Profitability
Return on equity−74.8% (better)−466%
Financial health
Debt / equity0.00–
Current ratio4.04 (better)0.83
Altman Z-score−10.47 (better)−21.38
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions15.7%18.6%
Held by insiders16.7%–
Short interest, % of float11.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.